Avigen (Biotechnology) Overview

  • Year Founded
  • 1992

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 12

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $42.9M

Avigen (Biotechnology) General Information

Description

Operator of a development stage biopharmaceutical company intended to focus on smart drug development and value-creating partnerships. The company's focus lies in the development of gene therapy products, based on its AAV (adeno-associated virus) delivery platform technology, gene delivery products, which are designed for direct administration to patients in order to achieve expression of therapeutic proteins within the body and product development programs in hemophilia and Parkinson's diseases as well.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly Accelerator/Incubator backed
Corporate Office
  • 1301 Harbor Bay Parkway
  • Alameda, CA 94502
  • United States
+1 (510)
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Acquirer
Vertical(s)
Corporate Office
  • 1301 Harbor Bay Parkway
  • Alameda, CA 94502
  • United States
+1 (510)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Avigen (Biotechnology) Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Merger/Acquisition 18-Dec-2009 $42.9M Completed Generating Revenue
5. Buyout/LBO 15-Jan-2009 Cancelled Generating Revenue
4. PIPE 25-May-2006 Completed Generating Revenue
3. PIPE 12-Feb-2001 Completed Generating Revenue
2. IPO 22-May-1996 $20M $20M Completed Generating Revenue
1. Accelerator/Incubator Completed Generating Revenue
To view Avigen (Biotechnology)’s complete valuation and funding history, request access »

Avigen (Biotechnology) Patents

Avigen (Biotechnology) Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2009017625-A1 Treatment of depression, phychosis, and anxiety Inactive 27-Jul-2007
WO-2008137012-A1 Use of a glial attenuator to prevent amplified pain responses caused by glial priming Inactive 03-May-2007
WO-2008133937-A2 Compositions of tolperisone Inactive 26-Apr-2007
WO-2008133937-A3 Compositions of tolperisone Inactive 26-Apr-2007
WO-2008103234-A1 Process methods for fucoidan purification from seaweed extracts Inactive 23-Feb-2007 C08B37/0063
To view Avigen (Biotechnology)’s complete patent history, request access »

Avigen (Biotechnology) Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Avigen (Biotechnology) Former Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds
BVF Partners Hedge Fund Minority
Bayer CropScience Corporation Minority
Federated Hermes (Pittsburgh) Asset Manager Minority
Johns Hopkins Technology Ventures Accelerator/Incubator
To view Avigen (Biotechnology)’s complete investors history, request access »

Avigen (Biotechnology) FAQs

  • When was Avigen (Biotechnology) founded?

    Avigen (Biotechnology) was founded in 1992.

  • Where is Avigen (Biotechnology) headquartered?

    Avigen (Biotechnology) is headquartered in Alameda, CA.

  • What is the size of Avigen (Biotechnology)?

    Avigen (Biotechnology) has 12 total employees.

  • What industry is Avigen (Biotechnology) in?

    Avigen (Biotechnology)’s primary industry is Biotechnology.

  • Is Avigen (Biotechnology) a private or public company?

    Avigen (Biotechnology) is a Private company.

  • What is the current valuation of Avigen (Biotechnology)?

    The current valuation of Avigen (Biotechnology) is .

  • What is Avigen (Biotechnology)’s current revenue?

    The current revenue for Avigen (Biotechnology) is .

  • How much funding has Avigen (Biotechnology) raised over time?

    Avigen (Biotechnology) has raised $56.1M.

  • Who are Avigen (Biotechnology)’s investors?

    BVF Partners, Bayer CropScience, Federated Hermes (Pittsburgh), and Johns Hopkins Technology Ventures have invested in Avigen (Biotechnology).

  • When was Avigen (Biotechnology) acquired?

    Avigen (Biotechnology) was acquired on 18-Dec-2009.

  • Who acquired Avigen (Biotechnology)?

    Avigen (Biotechnology) was acquired by MediciNova.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process